The Joe Rogan ExperienceJoe Rogan Experience #1671 - Bret Weinstein & Dr. Pierre Kory
CHAPTERS
- 0:00 – 1:23
Emergency episode setup: who Dr. Pierre Kory is and why this conversation is urgent
Joe frames the episode as an "emergency podcast" prompted by escalating censorship and the need to discuss COVID treatment debates quickly. Dr. Pierre Kory introduces himself, his ICU/pulmonary background, and the FLCCC’s role in developing COVID protocols—especially outpatient approaches centered on ivermectin.
- 1:23 – 3:06
Bret Weinstein’s COVID analysis background and how ivermectin entered the picture
Bret describes how he and Heather Heying built the DarkHorse COVID coverage by reading papers live and updating conclusions as evidence changed. He explains how early signals around ivermectin surfaced during that ongoing review process.
- 3:06 – 4:59
Early ivermectin signal: lab evidence and “bench to bedside” urgency
Dr. Kory recounts the initial in-vitro ivermectin study (cell culture/monkey kidney cells) showing dramatic reduction of viral material, which some regions translated into clinical use during an emergency. The group emphasizes ivermectin’s long safety record and low cost as key context.
- 4:59 – 8:05
YouTube strikes and the problem of defining “deceptive medical information”
Joe and Bret detail YouTube’s strikes, removed videos, and confusing enforcement, including labeling content as "spam" or "deceptive medical information." They argue platform rules defer to agencies (CDC/FDA/WHO) even when those agencies conflict or lag evidence.
- 8:05 – 18:38
Agency contradictions: remdesivir, vaccines, and airborne/aerosol transmission
The guests cite examples where major health bodies disagree, focusing on remdesivir adoption in the U.S. vs WHO skepticism and disputes over airborne transmission. They argue these mismatches illustrate why open scientific debate is necessary and why agency alignment cannot be treated as unquestionable truth.
- 18:38 – 29:28
Lab-leak narrative reversal and the broader theme: misinformation vs disinformation
Joe and Bret discuss how lab-leak discussion was once censored but later became mainstream, using it as a cautionary example of premature “consensus.” Dr. Kory frames this as disinformation tactics used to suppress inconvenient science, drawing parallels to ivermectin.
- 29:28 – 40:48
How “real” scientific consensus forms vs. top-down consensus enforced by platforms
Bret contrasts organic scientific consensus (built through challenge and correction) with “official consensus” declared during an emerging pandemic. The group argues platforms and agencies are suppressing the necessary adversarial process that normally refines truth.
- 40:48 – 57:48
Ivermectin evidence basics: RCTs, meta-analyses, and what critics are (and aren’t) saying
Bret and Dr. Kory outline the evidence landscape: many trials, noisy signals, and meta-analyses intended to pool results and reduce protocol-specific error. They argue critics improperly demand only large single RCTs while dismissing the cumulative evidence and the precautionary principle for a safe drug.
- 57:48 – 1:11:21
Prophylaxis claim: prevention rates, dosing nuances, and the “end the pandemic” argument
The discussion spotlights ivermectin as prevention (prophylaxis), citing a meta-analysis line suggesting large reduction in infection and specific studies in healthcare workers with dramatic contrasts vs controls. They discuss dosing frequency, co-interventions (e.g., carrageenan spray), and how prevention could theoretically drive extinction.
- 1:11:21 – 1:22:23
Follow-the-money hypothesis: patents, EUAs, Merck’s reversal, and the $3B antiviral push
Bret and Dr. Kory speculate that profit incentives and regulatory structures explain the hostility to cheap repurposed drugs. They highlight Merck’s unusual stance against its own product, the role of Emergency Use Authorizations (EUAs), and public funding aimed at new patented antivirals despite existing candidates.
- 1:22:23 – 2:06:09
Real-world rollouts: Mexico’s test-and-treat, Argentina/La Pampa, India, and variant claims
Dr. Kory cites population-level “natural experiments” where ivermectin adoption allegedly correlates with rapid declines in hospitalizations and deaths. The conversation argues these large-scale signals are being ignored by major media and agencies, and discusses why effects should plausibly extend across variants due to multiple mechanisms.
- 2:06:09 – 2:23:33
Long COVID and post-vaccine syndromes: proposed mechanisms, dosing, and the FLCCC protocols
The guests pivot to long COVID, describing symptom clusters (fatigue, brain fog, cognitive issues) and proposing persistent inflammation triggered by lingering viral proteins. Dr. Kory reports clinical experiences using ivermectin (sometimes with steroids) and references FLCCC’s iRecover guidance, while noting limited formal trial data for long COVID specifically.
- 2:23:33 – 2:54:50
Censorship, public health messaging vs science, and the stakes of blocking debate
They argue that suppressing discussion prevents clinicians from learning, adapting, and saving lives—drawing parallels to earlier steroid debates where sharing frontline insights changed care. Bret distinguishes public health messaging (game theory, simplification) from scientific truth-seeking, warning that censorship tools inevitably get captured and misused.
